N-[3-(2-呋喃基)丙烯酰]-L-苯丙氨酰-甘氨酰-甘氨酸 | 64967-39-1

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 甘氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-[3-(2-呋喃基)丙烯酰]-L-苯丙氨酰-甘氨酰-甘氨酸
• 中文别名: N-(3-(2-呋喃酰)丙烯酰-苯氨酰-谷氨酰-谷氨酸；N-(3-(2-呋喃基)丙烯氧基)-L-苯丙胺酰-G甘氨酰-甘氨酸；FAPGG；N-[3-(2-呋喃基)丙烯酰]-L-苯丙氨酰甘氨酰甘氨酸
• 英文名称: Fapgg
• 英文别名: 2-[[2-[[(2S)-2-[[(E)-3-(furan-2-yl)prop-2-enoyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]acetic acid
• CAS: 64967-39-1
• 化学式: C₂₀H₂₁N₃O₆
• 分子量: 399.4
• InChiKey: ZDLZKMDMBBMJLI-FDMDGMSGSA-N

物化性质

• 熔点：
  245 °C (dec.)(lit.)
• 沸点：
  842.3±65.0 °C(Predicted)
• 密度：
  1.321±0.06 g/cm3(Predicted)
• 溶解度：
  NH4OH1M：50 mg/mL，澄清至微浑浊，黄色

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  29
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  138
• 氢给体数：
  4
• 氢受体数：
  6

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S22,S24/25
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  29321900

文献信息

• Metallo-proteinase inhibitory agent
  申请人：Société des Produits Nestlé S.A.

  公开号：EP1359157A1

  公开（公告）日：2003-11-05

  The present invention relates to an active agent, in particular a metalloproteinase inhibitory agent comprising casein-derived peptides obtained by hydrolysis of casein by a food grade bacteria. The invention also relates to the manufacture of a agent, in which a food grade bacteria of the genus Lactobacillus helveticus is contacted with casein in order to perform an hydrolysis and obtain casein-derivated peptides exhibiting metalloproteinases inhibitory property. The present invention also concern the isolated and purified inhibitory peptides obtained by hydrolysis of casein by the said bacteria.

  本发明涉及一种活性剂，特别是一种金属蛋白酶抑制剂，该活性剂包含通过食品级细菌水解酪蛋白而获得的酪蛋白衍生肽。本发明还涉及一种制剂的制造，在这种制剂中， helveticus 乳酸杆菌属的食品级细菌与酪蛋白接触，以进行水解并获得具有金属蛋白酶抑制特性的酪蛋白衍生肽。本发明还涉及通过上述细菌水解酪蛋白获得的分离和纯化的抑制肽。
• Dilution based inhibition assay
  申请人：Debreceni Egyetem

  公开号：EP2664920A1

  公开（公告）日：2013-11-20

  The present invention provides for a process to assess the level of reversible inhibition of an enzyme by an inhibitor, in particular in the field of assessment the effectiveness of a medical treatment. In a particularly preferred embodiment the effectiveness of angiotensin converting enzyme (ACE) inhibitor (ACEi) therapy is disclosed. The invention also relates to uses of enzyme substrates and kits for the assessment of inhibition level as well as an apparatus designed for use in a process of the present invention.

  本发明提供了一种评估抑制剂对酶的可逆抑制水平的方法，特别是在评估医疗效果方面。在一个特别优选的实施方案中，公开了血管紧张素转换酶（ACE）抑制剂（ACEi）治疗的有效性。本发明还涉及酶底物的用途、评估抑制水平的试剂盒以及设计用于本发明过程的仪器。
• Renin-angiotensin system in diabetes mellitus
  申请人：——

  公开号：US20030158090A1

  公开（公告）日：2003-08-21

  The present invention provides novel methods of treatment of diabetes mellitus as well as methods of diagnosing the susceptibility of hypoglycaemia in an individual. The method of treatment includes administering to an individual a sufficient amount of at least one inhibitor of the renin-angiotensin II system and at least one antidiabetic, for example insulin. Another objective of the present invention is to provide methods of preventing hypoglycaemia in an individual in need thereof comprising administering to said individual a pharmaceutical effective amount of an inhibitor of the renin-angiotensin II system. In particular, such an individual may be an individual suffering from diabetes mellitus. A further objective of the present invention is to provide methods to diagnose the susceptibility to hypoglycaemia of an individual comprising detecting within a predetermined tissue sample the genotype of the angiotensin-converting enzyme (ACE) gene; or detecting within a predetermined tissue sample the activity of ACE; and correlating said genotype or activity to the susceptibility of hypoglycaemia.

  本发明提供了治疗糖尿病的新方法以及诊断个体低血糖易感性的方法。治疗方法包括向个体施用足量的至少一种肾素-血管紧张素 II 系统抑制剂和至少一种抗糖尿病药物，例如胰岛素。本发明的另一个目的是为有需要的个体提供预防低血糖症的方法，包括向所述个体施用药物有效量的肾素-血管紧张素 II 系统抑制剂。特别是，这种人可能是糖尿病患者。本发明的另一个目的是提供诊断个体低血糖易感性的方法，包括在预定组织样本中检测血管紧张素转换酶（ACE）基因的基因型；或在预定组织样本中检测血管紧张素转换酶的活性；以及将所述基因型或活性与低血糖易感性相关联。
• METALLOPROTEINASE INHIBOTORY AGENT
  申请人：Juillerat Marcel-Alexandre

  公开号：US20070258914A1

  公开（公告）日：2007-11-08

  The present invention relates to an active agent, in particular a metalloproteinase inhibitory agent of casein-derived peptides obtained by hydrolysis of casein by a food grade bacteria. The invention also relates to the manufacture of an active agent, in which a food grade bacteria of the genus Lactobacillus helveticus is contacted with casein in order to perform a hydrolysis and obtain casein-derived peptides exhibiting metalloproteinases inhibitory property. The present invention also includes isolated and purified inhibitory peptides obtained by hydrolysis of casein by the bacteria.
• PROTEIN PRODUCT FOR MODIFYING CARDIOVASCULAR HEALTH
  申请人：Fitzgerald Dick

  公开号：US20110130637A1

  公开（公告）日：2011-06-02

  A composition for use in the treatment or prophylaxis of conditions mediated by endothelial function in mammals is provided. The composition includes a milk protein hydrolysate generated by treating milk or milk whey protein with a proteolytic enzyme having subtilisin or subtilisin-like activity and/or glutamyl endopeptidase or glutamyl endopeptidase-like activity. The composition is useful in the management of vascular conditions.